Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Phase Ib/II, open-label, dose escalation and expansion clinical study of ADG106 in combination with KEYTRUDA® (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies

Next Previous
Trial Profile

A Global Phase Ib/II, open-label, dose escalation and expansion clinical study of ADG106 in combination with KEYTRUDA® (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADG 106 (Primary) ; Pembrolizumab (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-D12

Most Recent Events

  • 30 Aug 2022 According to an Adagene media release. given the prioritization of its two anti-CTLA-4 clinical programs and potential of its next generation anti-CD137 therapy, ADG206, Adagene does not intend to proceed with the current trial.
  • 30 Aug 2022 Status changed from planning to discontinued, according to an Adagene media release.
  • 26 Aug 2021 According to an Adagene media release, company to implement biomarker-enriched tumor targeting strategy for this trial in the U.S. and Asia Pacific (APAC). Data from this trial anticipated in 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top